Abstract
Neurocognitive complications such as leukoencephalopathy after high-dose intravenous methotrexate therapy （HD‒MTX） are important for childhood cancer survivors, because these neurocognitive complications affect the quality of life of patients. We identified Protein A in cerebrospinal fluid （CSF） as an MTX-related neurotoxicity-associated protein by proteomics analysis. In a series of CSF samples obtained during MTX-containing chemotherapy of 17 pediatric patients with hematological malignancy, Protein A was elevated at onset and just before onset of neurocognitive complications associated with HD‒MTX or intrathecal MTX therapy in the patients. The concentration of MTX in CSF was higher in the 5 g/m2 HD‒MTX group than the 2 g/m2 HD‒MTX group. We will evaluate the significance of Protein A in CSF as a biomarker for leukoencephalopathy in a larger cohort. We will also study the association between Protein A and MTX in CSF and leukoencephalopathy by pharmacogenetic approach.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
